ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 628,80
0,76%
Dow Jones
38 834,86
0,15%
DAX
18 131,97
0,32%
Brent Oil
84,76
-0,03%
Bitcoin
65 507,96
0,57%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. MaxCyte Inc (MXCT)

  7. MaxCyte Inc (MXCT) Actualités

MXCT MaxCyte Inc

4,40
-0,29 (-6,18%)
19 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
MaxCyte Inc MXCT NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,29 -6,18% 4,40 01:57:03
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
4,76 4,40 4,76 4,41 4,69
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
13/6/202423:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/6/202423:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/6/202423:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/6/202423:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/6/202423:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/6/202423:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/6/202422:45EDGAR2Form 8-K - Current report
10/6/202423:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/5/202414:05GLOBEMaxCyte to Participate in William Blair 44th Annual Growth..
22/5/202414:05GLOBEMaxCyte Signs Strategic Platform License Agreement with..
07/5/202423:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202422:14EDGAR2Form 8-K - Current report
07/5/202422:05GLOBEMaxCyte Reports First Quarter 2024 Financial Results and..
10/4/202414:05GLOBEMaxCyte to Report First Quarter 2024 Financial Results on..
02/4/202414:05GLOBEMaxCyte Signs Strategic Platform License with Be Biopharma..
12/3/202421:05GLOBEMaxCyte Reports Fourth Quarter and Full Year 2023 Financial..
05/3/202422:15EDGAR2Form 8-K - Current report
04/3/202423:39EDGAR2Form 3 - Initial statement of beneficial ownership of..
04/3/202422:05GLOBEMaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023..
26/2/202422:22EDGAR2Form 144 - Report of proposed sale of securities
14/2/202422:26EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202418:25EDGAR2Form SC 13G - Statement of acquisition of beneficial..
09/2/202414:05GLOBEMaxCyte to Report Fourth Quarter and Full Year 2023..
01/2/202422:25EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
30/1/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202414:05GLOBEMaxCyte and Wugen Sign Strategic Platform License to..
26/1/202422:45EDGAR2Form 8-K - Current report
26/1/202417:49EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
23/1/202414:05GLOBEMaxCyte Signs Strategic Platform License with Imugene to..
08/1/202422:15EDGAR2Form 8-K - Current report
08/1/202422:05GLOBEMaxCyte Announces Preliminary Unaudited Fourth Quarter and..
04/1/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202414:05GLOBEMaxCyte and Lion TCR form Partnership to Support Global..
02/1/202408:00GLOBEMaxCyte Confirms Appointment of Maher Masoud as President,..
28/12/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/12/202322:30EDGAR2Form 8-K - Current report
11/12/202322:05GLOBEMaxCyte Announces CEO Transition and Updates Revenue..
06/12/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/12/202323:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/11/202322:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/11/202322:32EDGAR2Form 144 - Report of proposed sale of securities
17/11/202322:05EDGAR2Form SC 13G - Statement of acquisition of beneficial..
16/11/202322:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/11/202314:05GLOBEMaxCyte Joins the Alliance for mRNA Medicines (AMM) as a..
08/11/202323:12EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202322:12EDGAR2Form 8-K - Current report
08/11/202322:05GLOBEMaxCyte Reports Third Quarter 2023 Financial Results and..
06/11/202322:05GLOBEMaxCyte to Participate in Two Upcoming Investor Conferences
04/10/202322:14EDGAR2Form 8-K - Current report
04/10/202322:05GLOBEMaxCyte Announces Preliminary Third Quarter 2023 Revenue and..

Dernières Valeurs Consultées

NASDAQ
MXCT
MaxCyte
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés